---
schema_version: "secwatch.filing_event.v1"
accession: "0001552781-24-000494"
form_type: "8-K"
ticker: "SWKHL"
cik: "0001089907"
company_name: "SWK Holdings Corp"
filed_at: "2024-08-15T23:59:59+00:00"
generated_at: "2026-05-31T08:56:51.260357+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# SWK Holdings Q2 2024 revenue up 21% to $11.5M; GAAP net income $4.4M vs $3.9M YoY

## Summary
- Finance receivables segment revenue rose 15.3% to $10.7M; adjusted non-GAAP net income fell to $6.5M from $7.6M YoY.
- Provision for credit losses totaled $4.1M driven by impairments on Trio ($2.1M) and Exeevo ($2.2M) loans.
- Non-accrual finance receivables were $22.4M at June 30, 2024; portfolio includes Flowonix, Exeevo, Ideal Implant, Best ABT, Trio.
- Post-quarter closed up to $11M royalty financing with Relief Therapeutics; $5.8M advanced at close.
- Non-GAAP tangible financing book value per share grew 6.4% to $20.17; GAAP book value per share $22.75.

## SEC filing metadata
- accession: 0001552781-24-000494
- form_type: 8-K
- ticker: SWKHL
- cik: 0001089907
- company_name: SWK Holdings Corp
- filed_at: 2024-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1089907/000155278124000494/0001552781-24-000494-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1089907/000155278124000494/e24351_swkh-8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001552781-24-000494
- JSON: https://secwatch.observer/filing/0001552781-24-000494.json
- Plain text: https://secwatch.observer/filing/0001552781-24-000494.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.